Vertex resumed with an Overweight at Morgan Stanley

Morgan Stanley resumed coverage of Vertex with an Overweight rating and $25 price target. The end of a multi-year growth investment program positions Vertex for accelerating revenue growth and free cash flow margin expansion, the analyst tells investors in a research note. The firm believes the market is underpricing the company’s “structural inflection.”